Agios Pharmaceuticals targets rare blood disorders with a marketed anemia drug and a focused clinical-stage pipeline.

PYRUKYND® (mitapivat) worldwide net revenues of $20.0 million in fourth quarter and $54.0 million for full yearAQVESME™ (mitapivat) for ...

Agios Pharmaceuticals has reported full-year 2025 results, with revenue rising to US$54.03 million from US$36.50 million a year earlier, while swinging from net income of US$673.73 million to a net ...

Q4 2025 Management View CEO Brian Goff emphasized the company's 2026 strategic priorities, stating, "we're focused on executing a high-impact launch of AQVESME for the treatment of thalassemia in the ...

Detailed price information for Agios Pharmaceuticals (AGIO-Q) from The Globe and Mail including charting and trades.

After going it alone for the past 14 years, Agios is ready to find a dance partner to help move its pipeline forward. But as part of the hunt for a company or companies that may nod back to Agios’ ...

Agios Pharmaceuticals AGIO reported a loss of $1.85 per share in the fourth quarter of 2025, narrower than the Zacks ...

Agios Pharmaceuticals’ pivot from cancer to rare diseases culminated in the $1.8 billion sale of its oncology business. But the biotech still needs capital to support a product launch and additional ...

– Company Expects to Initiate Phase 2b Study in Mid-2024 – CAMBRIDGE, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (AGIO), a leader in the field of cellular metabolism ...

Cambridge, Massachusetts-based Agios will market its new product, a twice-daily tablet, under the name “Pyrukynd.” The FDA’s Thursday approval covers use of the drug in adults who have an inherited ...

– 40 Percent of Low Transfusion Burden Cohort Achieved Transfusion Independence; One Study Patient Achieved Hemoglobin Response Endpoint – – Safety Profile Consistent with Data Reported in Healthy ...